Several of LBG’s consultants recently published a joint article on Return on Investment (ROI) calculations and tools used by pharmaceutical and biotechnology companies in evaluating product returns, guiding decisions on further product development or terminating programs prior to company losses. In the article they present a framework for executing ROI calculations to enable investment or... Read More
LBG consultants Lauren R. Schoukroun-Barnes, Joseph Rininger, Kristi Sarno, and Susan Dexter interviewed CAR-T Innovators and Manufacturers to better understand the difficulties surrounding manufacturing. Specifically, the Innovators were asked about the criteria they look for in a CDMO. Without exception, Innovator companies stated CDMO capacity and flexibility were top priorities. These criteria are priorities for... Read More
LBG consultants Kristi Sarno and Cassidy Cantin performed market research and analyzed the results in an article “Outsourcing Biosimilar Development“, published in BioProcess International’s March 2017 Featured Report. LBG interviewed six executives at companies that are either sponsoring biosimilar candidates or are CDMOs that manufacture biosimilars to identify some challenges and understand how CDMOs are adapting to capture this portion of the biopharmaceutical... Read More
BALTIMORE – August 31, 2016 – Latham BioPharm Group (LBG), a premier provider of life science consulting services to customers in the federal and commercial sectors, today announced the expansion of company operations and the opening of new office space in Baltimore, MD. The new space is located within the heart of the Inner Harbor,... Read More
Interested in our services? Contact us today to setup an appointment.